News Formycon AG

Equities

FYB

DE000A1EWVY8

Market Closed - Xetra Other stock markets 11:36:15 2024-04-19 am EDT			After market 02:00:23 pm
38.65 ^EUR	-2.64%		38.18	-1.23%

Mar. 18	Formycon, Fresenius Kabi Sign Settlement Deal with Johnson & Johnson for Ustekinumab Biosimilar	MT
Mar. 18	Fresenius Settles With Johnson & Johnson to Market Stelara Alternative	DJ

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Convincing overall performance - Formycon reports preliminary results for the financial year 2023 and exceeds forecast	Apr. 12	EQ
Formycon AG publishes preliminary figures for the 2023 financial year and guidance for the 2024 financial year	Apr. 12	EQ
Formycon announces commercial launch of FYB201 (Ranibizumab) in Canada (RanoptoTM) and Switzerland (Ranivisio®)	Apr. 11	EQ
Fresenius Kabi And Formycon Reach Settlement Agreement For Ustekinumab Biosimilar Candidate In Europe And Canada	Apr. 03	AQ
Updates On Aflibercept BPCIA Litigation	Mar. 26	AQ
Formycon, Fresenius Kabi Sign Settlement Deal with Johnson & Johnson for Ustekinumab Biosimilar	Mar. 18	MT
Fresenius Settles With Johnson & Johnson to Market Stelara Alternative	Mar. 18	DJ
Formycon and Fresenius Kabi reach settlement agreement for ustekinumab biosimilar candidate FYB202 in Europe and Canada	Mar. 18	EQ
Formycon Wins Regulatory Nod for Lucentis Biosimilar in Saudi Arabia	Mar. 11	MT
FYB201/Ranibizumab keeps gaining momentum with approvals and launches in the MENA region	Mar. 11	EQ
Updates On Aflibercept BPCIA Litigation	Feb. 19	AQ
Formycon Sells 9% Interest to Gedeon Richter for EUR83 Million	Jan. 30	MT
Gedeon Richter becomes strategic investor of Formycon via equity investment	Jan. 29	EQ
Formycon resolves on cash capital increase of EUR 82.84 million – all new shares were subscribed by Gedeon Richter as new strategic investor	Jan. 29	EQ
Formycon Ranibizumab Biosimilar FYB201/CIMERLI® achieved a market share of 38% in the United States in December 2023	Jan. 18	EQ
Regeneron's Disputes With Celltrion, Samsung Bioepis, And Formcycon On Service And Personal Jurisdiction In Aflibercept BPCIA Litigation	Jan. 11	AQ
Formycon to present at the 42nd Annual J.P. Morgan Healthcare Conference	Jan. 04	EQ
Deutsche Borse to publish cash market annual statistics 2023	Jan. 03	AQ
EU Medicines Regulator Accepts Formycon's Marketing Authorization Application for Eylea Biosimilar	Dec. 27	MT
Formycon announces EMA acceptance of the MAA for FYB203, a biosimilar candidate to Eylea® (Aflibercept)	Dec. 27	EQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Formycon AG

Equities

FYB

DE000A1EWVY8

Summary

Filters